ライフサイエンスコーパス: Papanicolaou test

1 conducted, which included a mammogram and a Papanicolaou test.

2 e excluded as they were likely not due for a Papanicolaou test.

3 the number of previous consecutive negative Papanicolaou tests.

4 mmography, 14.7% [95% CI, 13.7%-15.6%] had a Papanicolaou test, 23.3% [95% CI, 22.6%-24.0%] had a PSA

5 e breast imaging, 64 (16.9%) had undergone a Papanicolaou test, 274 (72.5%) rarely or never examined

6 .001), mammography (69.4% vs 75.1%; P<.001), Papanicolaou tests (69.2% vs 77.1%; P<.001), and psychia

7 as defined as screening every 3 years with a Papanicolaou test alone for women aged 21 to 29 years an

8 29 years and screening every 3 years with a Papanicolaou test alone or every 5 years with high-risk

9 lowed up every 6 months for 24 months with a Papanicolaou test and confirmatory biopsy.

10 For example, for both Papanicolaou test and mammography, areas that changed fr

11 V in Kenya underwent cervical screening with Papanicolaou testing and confirmatory biopsy.

12 of age and an average of 209,324 additional Papanicolaou tests and 11,502 colposcopic examinations i

13 gative test, an average of 69,665 additional Papanicolaou tests and 3861 colposcopic examinations wou

14 u tests, as well as the number of additional Papanicolaou tests and colposcopic examinations that wou

15 ds to increased rates of abnormal results of Papanicolaou tests and contributes to the increased rate

16 Spatial analyses of mammography, Papanicolaou test, and colorectal cancer screening in th

17 Medical record documentation of mammography, Papanicolaou testing, and colorectal cancer screening ac

18 tible health plan fully covered mammography, Papanicolaou tests, and fecal occult blood testing (FOBT

19 -based cytology and computerized analysis of Papanicolaou tests are examples of attempts at this appr

20 e of inhabitants who are up to date with the Papanicolaou test, are of Asian race, and have private i

21 ithin three years after one or more negative Papanicolaou tests, as well as the number of additional

22 to be percentage of women screened with the Papanicolaou test, Asian race, private insurance, and ce

23 creasing screening uptake of mammography and Papanicolaou testing, but their role in CRC screening is

24 uidelines suggest that the intervals between Papanicolaou tests can be extended to three years among

25 ion of HPV genotyping and cervical cytology (Papanicolaou testing) can identify the risk of precancer

26 mammography (95% CI, 0.06 to 0.19), 0.07 for Papanicolaou testing (CI, 0.01 to 0.12), and 0.13 for co

27 n between each primary outcome (mammography, Papanicolaou test, colonoscopy, influenza vaccine, and p

28 onusers, independent of sexual behavior, and Papanicolaou test diagnosis (AHR: 0.67 [95% CI: .49-.93]

29 the order in which they were performed (eg, Papanicolaou test followed by human papillomavirus [HPV]

30 a primary care clinician, had not received a Papanicolaou test for at least 3 years and 5 months, and

31 nt, and the positive predictive value of the Papanicolaou test for detecting vaginal cancer was 0 per

32 el, the estimated risk of cancer with annual Papanicolaou tests for three years was 2 in 100,000 amon

33 clinic, and were overdue for screening (ie, Papanicolaou test >=4 years ago or high-risk HPV test >=

34 Screening programs, such as colposcopy with Papanicolaou testing, have greatly improved mortality ra

35 g had a mammogram in the previous 2 years, a Papanicolaou test in the previous 3 years, and a fecal t

36 0.58 with usual care; the proportion who had Papanicolaou testing increased from 0.71 to 0.78 with th

37 squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined s

38 have had three or more consecutive negative Papanicolaou tests is associated with an average excess

39 th plan enrollment duration, time since last Papanicolaou test, mammography, comorbidities, and color

40 Individuals who received a Papanicolaou test more than 1 to 3 years prior to a HINT

41 eater with longer vs shorter time since last Papanicolaou test (no prior Papanicolaou test: RRs, 1.85

42 ation size, health-related variables (use of Papanicolaou test, obesity), income variables (median ho

43 testing and typing from samples obtained for Papanicolaou testing occurred every 6 months.

44 s and were based on either wellness visit or Papanicolaou test-only visit costs.

45 .29 (95% CI, $146.20-$146.38) using Medicare Papanicolaou test-only visits as the cost source.

46 reproductive health care services, including Papanicolaou tests or birth control, experienced in the

47 mammography (OR, 0.74 [95% CI, 0.71-0.77]), Papanicolaou test (OR, 0.84 [95% CI, 0.81-0.87]), influe

48 erican women to have an abnormal result of a Papanicolaou test (OR, 1.58; 95% CI, 1.05-2.39).

49 (mammography: OR, 0.32 [95% CI, 0.27-0.38]; Papanicolaou test: OR, 0.49 [95% CI, 0.44-0.54]; influen

50 : odds ratio [OR], 0.73 [95% CI, 0.67-0.80]; Papanicolaou test: OR, 0.78 [95% CI, 0.72-0.85]; influen

51 of cancer screening procedures (mammography, Papanicolaou test, prostate-specific antigen [PSA], and

52 Papanicolaou testing rates among rural females are a con

53 ionally representative research has examined Papanicolaou testing rates from before the pandemic in 2

54 d cross-sectional study found that past-year Papanicolaou testing rates were lower in 2022 than 2019,

55 In 2022, unadjusted past-year Papanicolaou testing rates were significantly lower amon

56 Papanicolaou test results from 740 HIV-positive women (m

57 ual behavior, genital tract coinfection, and Papanicolaou test results were assessed at baseline and

58 time since last Papanicolaou test (no prior Papanicolaou test: RRs, 1.85-3.25; >=10 years: RR, 2.78;

59 creation of a diagnostic system to digitize Papanicolaou test samples and analyze them using a cloud

60 Similarly, Papanicolaou test screening became more uniform in more

61 , 8.6%-9.1%) vs 22.0% (95% CI, 21.7%-22.5%); Papanicolaou test screening was received by 5.8% (95% CI

62 ilization showed a positive correlation with Papanicolaou test use (r = 0.75, P < .001), median house

63 Papanicolaou testing using atypical squamous cells of un

64 testing, and liquid-based cytologic testing (Papanicolaou testing) was performed regularly.

65 vulvovaginal samples for HPV DNA testing and Papanicolaou testing were collected at gynecologic exami

66 Adjusted odds of past-year Papanicolaou testing were lower in 2022 than 2019 (odds

67 gh-grade squamous intraepithelial lesions in Papanicolaou test whole-slide images.

68 s for 24 months with hrHPV cervical swab and Papanicolaou test with confirmatory biopsy.

69 squamous cells of undetermined significance Papanicolaou test with satisfactory results for all 4 HP

70 They underwent periodic Papanicolaou testing, with colposcopy or biopsy for dete

71 Those who reported having a Papanicolaou test within the past 3 years were considere

72 Self-reported receipt of a Papanicolaou test within the past year.

73 hs, a current primary care clinician, and no Papanicolaou test within the prior 3 years and 5 months

74 outine mammography (women aged 40-74 years), Papanicolaou test (women aged 21-65 years), colonoscopy